Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Rosacea
ADR ID BADD_A03896
ADR Hierarchy
23      Skin and subcutaneous tissue disorders
23.02      Skin appendage conditions
23.02.08      Rosaceas
23.02.08.001      Rosacea
Description A cutaneous disorder primarily of convexities of the central part of the FACE, such as FOREHEAD; CHEEK; NOSE; and CHIN. It is characterized by FLUSHING; ERYTHEMA; EDEMA; RHINOPHYMA; papules; and ocular symptoms. It may occur at any age but typically after age 30. There are various subtypes of rosacea: erythematotelangiectatic, papulopustular, phymatous, and ocular (National Rosacea Society's Expert Committee on the Classification and Staging of Rosacea, J Am Acad Dermatol 2002; 46:584-7). | A variant of rosacea. [MeSH]
MedDRA Code 10039218
MeSH ID D012393
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Acne rosacea | Rosacea | Rosacea-like dermatitis | Rosacea aggravated | Iatrosacea | Steroid rosacea | Acne Rosacea | Phymatous Rosacea | Rosacea, Phymatous | Ocular Rosacea | Rosacea, Ocular | Papulopustular Rosacea | Rosacea, Papulopustular | Erythematotelangiectatic Rosacea | Rosacea, Erythematotelangiectatic | Granulomatous Rosacea | Rosacea, Granulomatous
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00036Acitretin0.001250%
BADD_D00047Afatinib--
BADD_D00066Alendronic acid0.000264%
BADD_D00156Apremilast0.003810%
BADD_D00165Aripiprazole--
BADD_D00195Azathioprine0.001065%
BADD_D00197Azelaic acid0.003337%
BADD_D00294Brimonidine0.002747%
BADD_D00349Capecitabine--
BADD_D00424Cevimeline--
BADD_D00425Cevimeline hydrochloride--
BADD_D00490Clobetasol propionate--
BADD_D00491Clobetasone butyrate--
BADD_D00580Dapsone0.000807%
BADD_D00680Dimethyl fumarate0.000880%
BADD_D00720Doxepin--
BADD_D00751Eflornithine--
BADD_D00752Eflornithine hydrochloride--
BADD_D00800Erlotinib0.000246%
BADD_D00856Etoricoxib--
BADD_D00898Finasteride0.000234%
BADD_D01088Hydrocortisone butyrate--
BADD_D01213Isotretinoin0.000875%
BADD_D01232Ketorolac--
BADD_D01250Lasofoxifene--
BADD_D01253Lenalidomide0.005160%
BADD_D01281Levonorgestrel0.002789%
BADD_D01300Lisinopril0.000005%
BADD_D01336Macitentan0.000614%
BADD_D01418Methotrexate0.000307%
The 1th Page    1 2    Next   Last    Total 2 Pages